1. Home
  2. Browse
  3. cancer

cancer funding

100 open opportunities tagged cancer, across federal agencies and private foundations. Sorted by deadline.

PAR-25-153 • National Institutes of Health

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy.

3 review criteria on file
amount not statedDue 2026-09-074 days left
PAR-24-306 • National Institutes of Health

Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.

3 review criteria on file
$499,000award ceilingDue 2026-09-074 days left
PAR-25-325 • National Institutes of Health

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid…

3 review criteria on file
amount not statedDue 2026-09-107 days left
RFA-CA-27-008 • National Institutes of Health

NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)

Purpose This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human research study results through accrual in a variety of community settings.

7 review criteria on file
amount not statedDue 2026-09-1815 days left
RFA-CA-27-006 • National Institutes of Health

NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human research study results through accrual in a variety of community settings.

7 review criteria on file
amount not statedDue 2026-09-1815 days left
RFA-CA-27-007 • National Institutes of Health

NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed)

Purpose This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human research study results through accrual in a variety of community settings.

7 review criteria on file
amount not statedDue 2026-09-1815 days left
RFA-OD-25-011 • National Institutes of Health

Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)

Objective ORIP uses the P40 mechanism to support Animal and Biological Material Resource Centers in a variety of areas of biomedical science.

9 review criteria on file
amount not statedDue 2026-09-2118 days left
PAR-23-284 • National Institutes of Health

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE).

5 review criteria on file
amount not statedDue 2026-09-2522 days left
RFA-CA-27-012 • National Institutes of Health

Metastasis Research Network (U54 Clinical Trial Not Allowed)

Purpose The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will contribute to developing a comprehensive and cohesive understanding of cancer metastasis.

12 review criteria on file
$1,300,000award ceilingDue 2026-09-2522 days left
PAR-25-444 • National Institutes of Health

Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Purpose This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. NCI-Designated Cancer Centers serve as major sources of discovery into the nature of cancer and of the development of more effective approaches to prevention, diagnosis, and therapy.

11 review criteria on file
amount not statedDue 2026-09-2522 days left
HT942526KCRPAKCIECSA • Defense Health Agency Contracting Activity - DHACA

DoW Kidney Cancer, Academy of Kidney Cancer Investigators – Early-Career Scholar Award

Summary: Initially created in fiscal year 2019 (FY19), the Kidney Cancer Research Program (KCRP) Academy of Kidney Cancer Investigators (AKCI) is a unique interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty.

Review criteria on file
amount not statedDue 2026-09-2825 days left
HT942526KCRPIDA • Defense Health Agency Contracting Activity - DHACA

DoW Kidney Cancer, Idea Development Award

Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes.

Review criteria on file
amount not statedDue 2026-09-2825 days left
RFA-CA-24-026 • National Institutes of Health

National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.

8 review criteria on file
$400,000award ceilingDue 2026-09-2825 days left
RFA-OD-25-010 • National Institutes of Health

Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)

Experimental research models are indispensable for studying the genetic basis and pathobiological mechanisms underlying human diseases, identifying drug targets, and developing effective preventive and therapeutic approaches.

7 review criteria on file
amount not statedDue 2026-09-2825 days left
HT942526BCRPBTA4 • Defense Health Agency Contracting Activity - DHACA

DoW Breast Cancer, Breakthrough Award Level 4

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.

Review criteria on file
amount not statedDue 2026-09-3027 days left
HT942526BCRPBTA3 • Defense Health Agency Contracting Activity - DHACA

DoW Breast Cancer, Breakthrough Award Level 3

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.

Review criteria on file
amount not statedDue 2026-09-3027 days left
HT942526RCRPCA • Defense Health Agency Contracting Activity - DHACA

DoW Rare Cancers Concept Award

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers.

Review criteria on file
amount not statedDue 2026-09-3027 days left
HT942526BCRPTBCCA • Defense Health Agency Contracting Activity - DHACA

DoW Breast Cancer, Transformative Breast Cancer Consortium Award

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.

Review criteria on file
amount not statedDue 2026-09-3027 days left
HT942526OCRPOCCTAECI • Defense Health Agency Contracting Activity - DHACA

DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award

Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer.

Review criteria on file
amount not statedDue 2026-10-0128 days left
HT942526OCRPOCAECI • Defense Health Agency Contracting Activity - DHACA

DoW, Ovarian Cancer, Ovarian Cancer Academy – Early-Career Investigator Award

Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty.

Review criteria on file
amount not statedDue 2026-10-0128 days left
HT942526OCRPIIRA • Defense Health Agency Contracting Activity - DHACA

DoW, Ovarian Cancer, Investigator-Initiated Research Award

Summary: The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.

Review criteria on file
amount not statedDue 2026-10-0128 days left
HT942526OCRPCTA • Defense Health Agency Contracting Activity - DHACA

DoW Ovarian Cancer, Clinical Trial Award

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.

Review criteria on file
amount not statedDue 2026-10-0128 days left
HT942526OCRPPA • Defense Health Agency Contracting Activity - DHACA

DoW, Ovarian Cancer, Pilot Award

Summary: The Ovarian Cancer Pilot Award supports research that expands or modifies current thinking about and/or approaches in ovarian cancer, exploring innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.

Review criteria on file
amount not statedDue 2026-10-0128 days left
PAR-27-058 • National Institutes of Health

NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)

Purpose This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected previously.

4 review criteria on file
$500,000award ceilingDue 2026-10-05
PAR-25-145 • National Institutes of Health

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects.

3 review criteria on file
amount not statedDue 2026-10-05
PAR-25-043 • National Institutes of Health

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather…

3 review criteria on file
$500,000award ceilingDue 2026-10-05
PAR-24-311 • National Institutes of Health

Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (R01) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo .

3 review criteria on file
$500,000award ceilingDue 2026-10-05
PAR-25-175 • National Institutes of Health

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the…

3 review criteria on file
$500,000award ceilingDue 2026-10-05
PA-25-172 • National Institutes of Health

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) encourages applications for research in cancer control and population sciences.

3 review criteria on file
amount not statedDue 2026-10-05
HT942526PRCRPIPA • Defense Health Agency Contracting Activity - DHACA

DoW, Peer Reviewed Cancer, Impact Award

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas.

Review criteria on file
amount not statedDue 2026-10-05
PAR-25-069 • National Institutes of Health

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics.

3 review criteria on file
amount not statedDue 2026-10-05
PAR-25-167 • National Institutes of Health

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life,…

3 review criteria on file
amount not statedDue 2026-10-05
PAR-25-081 • National Institutes of Health

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM.

4 review criteria on file
$499,999award ceilingDue 2026-10-05
PAR-25-243 • National Institutes of Health

Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.

3 review criteria on file
amount not statedDue 2026-10-05
PAR-25-299 • National Institutes of Health

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)

). This NOFO is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025.

3 review criteria on file
amount not statedDue 2026-10-05
HT942526PRCRPIA • Defense Health Agency Contracting Activity - DHACA

DoW Peer Reviewed Cancer, Idea Award

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research.

Review criteria on file
amount not statedDue 2026-10-05
PAR-25-079 • National Institutes of Health

Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology,…

3 review criteria on file
$500,000award ceilingDue 2026-10-05
PAR-26-134 • National Institutes of Health

The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)

Purpose Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications proposing research projects that use integrative systems-level approaches to address a specific question in metastasis research.

3 review criteria on file
$500,000award ceilingDue 2026-10-05
PAR-27-073 • National Institutes of Health

Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)

Purpose Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support research in cancer epidemiology cohort studies that address specific knowledge gaps in cancer etiology and survivorship.

3 review criteria on file
amount not statedDue 2026-10-05
PAR-27-072 • National Institutes of Health

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

Purpose The goal for a bioengineering research grant (BRG) is to foster the development of an innovative technology, model, technique, design, or method that has the potential for a significant impact on biomedical research by infusing principles and concepts from the quantitative sciences.

3 review criteria on file
$500,000award ceilingDue 2026-10-05
HT942526PRCRPCTA • Defense Health Agency Contracting Activity - DHACA

DoW Peer Reviewed Cancer, Clinical Trial Award

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas.

Review criteria on file
amount not statedDue 2026-10-05
PAR-27-057 • National Institutes of Health

Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)

6 years.25 billion fewer life years for the United States population.

3 review criteria on file
$500,000award ceilingDue 2026-10-05
PAR-25-221 • National Institutes of Health

Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development,…

3 review criteria on file
amount not statedDue 2026-10-05
PAR-25-098 • National Institutes of Health

Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities.

3 review criteria on file
amount not statedDue 2026-10-05
HT942526PCARPFPTA • Defense Health Agency Contracting Activity - DHACA

DoW Pancreatic Cancer Research Program, Focused Pilot Award

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’…

Review criteria on file
amount not statedDue 2026-10-07
HT942526PCARPIDA • Defense Health Agency Contracting Activity - DHACA

DoW Pancreatic Cancer Research Program, Idea Development Award

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer.

Review criteria on file
amount not statedDue 2026-10-07
HT942526PCARPTRPA • Defense Health Agency Contracting Activity - DHACA

DoW Pancreatic Cancer Research Program, Translational Research Partnership Award

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications.

Review criteria on file
amount not statedDue 2026-10-07
PAR-25-248 • National Institutes of Health

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian…

3 review criteria on file
amount not statedDue 2026-10-09
PAR-27-025 • National Institutes of Health

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Not Allowed)

The overall goal of the NIH Research Career Development programs is to help ensure that a pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioral, and clinical research needs.

7 review criteria on file
amount not statedDue 2026-10-12
HT942526MRPFPARM • Defense Health Agency Contracting Activity - DHACA

DoW Melanoma Research Program Focused Program Award – Rare Melanomas

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas.

Review criteria on file
amount not statedDue 2026-10-14
PAR-23-286 • National Institutes of Health

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators.

Review criteria on file
amount not statedDue 2026-10-14
PAR-25-075 • National Institutes of Health

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment,…

3 review criteria on file
$250,000award ceilingDue 2026-10-14
PAR-24-304 • National Institutes of Health

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects.

3 review criteria on file
amount not statedDue 2026-10-14
PAR-25-074 • National Institutes of Health

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as…

3 review criteria on file
amount not statedDue 2026-10-14
HT942526MRPSRA • Defense Health Agency Contracting Activity - DHACA

DoW Melanoma Research Program Survivorship Research Award

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Survivorship Research Award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors,…

Review criteria on file
amount not statedDue 2026-10-14
HT942526MRPIA • Defense Health Agency Contracting Activity - DHACA

DoW Melanoma Research Program Idea Award

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Idea Award supports innovative, exploratory, high-risk/potentially high-reward research. Novelty and innovation are expected to be key aspects of the proposed project.

Review criteria on file
amount not statedDue 2026-10-14
HT942526MRPTSA • Defense Health Agency Contracting Activity - DHACA

DoW Melanoma Research Program Team Science Award

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Team Science Award supports a broad range of hypothesis-driven, multidisciplinary studies that have a short-term goal of advancing the state of the science in melanoma research and/or patient care.

Review criteria on file
amount not statedDue 2026-10-14
HT942526MRPMASA • Defense Health Agency Contracting Activity - DHACA

DoW Melanoma Research Program Melanoma Academy Scholar Award

Summary: Supports the addition of independent, early career investigators (Scholars) who are no more than seven years from their initial faculty appointment to the Melanoma Research Program (MRP) Melanoma Academy.

Review criteria on file
amount not statedDue 2026-10-14
PAR-23-287 • National Institutes of Health

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators.

Review criteria on file
amount not statedDue 2026-10-14
RFA-OD-27-005 • National Institutes of Health

INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)

Purpose The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome.

3 review criteria on file
amount not statedDue 2026-10-15

Showing 60 of 100.

See which cancer opportunities fit your work

An account is free and shows the full announcement, the review criteria reviewers score you against, and whether you are actually eligible — including the windows that close before the deadline does.

No card required.

Related subjects